Over the past few years, Eli Lilly (LLY +1.35%) has been offering investors a unique combination of safety and growth.
On June 30, Lilly agreed to hand a Chinese partner full commercial control of one of its cancer drugs. The move looks minor ...
1don MSNOpinion
Scott Galloway says GLP-1 drugs are a 'silver bullet' for America's woes, if we're not 'stupid enough' to get in the way
The drug has shown itself to be effective for weight loss — but its high price is making it a hard sell for many would-be ...
Our 24/7 Wall St. price target for Eli Lilly (NYSE:LLY | LLY Price Prediction) is $1,349.37, pointing to 12.5% upside from a recent price of $1,199.43. We rate LLY a buy with a 90% confidence score.
Over the years, Lilly has won approval for a wide variety of drugs across treatment areas, proving its technology works -- ...
Most of the U.S. stock market rose Friday after oil prices eased back to where they were before the war with Iran, but drops ...
The Dow Jones Industrial Average and the broader US stock market closed lower on Friday as investors continued rotating out ...
Most of the U.S. stock market is rising Friday after oil prices fell back to where they were before the war with Iran, but ...
Most of the U.S. stock market is rising after oil prices eased back to where they were before the war with Iran, but drops ...
Every weekday, the Investing Club releases the Homestretch; an actionable afternoon update just in time for the last hour of ...
ProQR Therapeutics has priced a registered direct offering of 27.6M ordinary shares at $1.81 per share, expecting to raise about $50M in gross proceeds before expenses. Separately ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results